Personal tools

Coexpression cluster:C3787: Difference between revisions

From FANTOM5_SSTAR

Jump to: navigation, search
(Created page with "{{Coexpression_clusters |full_id=C3787_CD14_Eosinophils_Neutrophils_Peripheral_aorta_Natural_CD4 |id=C3787 }}")
 
No edit summary
Line 2: Line 2:
|full_id=C3787_CD14_Eosinophils_Neutrophils_Peripheral_aorta_Natural_CD4
|full_id=C3787_CD14_Eosinophils_Neutrophils_Peripheral_aorta_Natural_CD4
|id=C3787
|id=C3787
|ontology_enrichment_celltype=CL:0000738!1.08e-28!140;CL:0002057!3.79e-23!42;CL:0002087!9.06e-23!119;CL:0000037!1.88e-22!172;CL:0000566!1.88e-22!172;CL:0000860!2.24e-22!45;CL:0002031!1.28e-21!124;CL:0002032!2.25e-21!165;CL:0000837!2.25e-21!165;CL:0000988!1.87e-20!182;CL:0000766!2.34e-18!76;CL:0000557!1.70e-14!71;CL:0002009!3.27e-14!65;CL:0002194!2.79e-13!63;CL:0000576!2.79e-13!63;CL:0000040!2.79e-13!63;CL:0000559!2.79e-13!63;CL:0000763!4.95e-13!112;CL:0000049!4.95e-13!112;CL:0000839!5.33e-13!70;CL:0000542!2.24e-08!53;CL:0000051!2.24e-08!53;CL:0000838!3.70e-08!52;CL:0002320!9.94e-08!365;CL:0000134!1.38e-07!358;CL:0002393!7.53e-07!9;CL:0002397!7.53e-07!9
|ontology_enrichment_disease=
|ontology_enrichment_uberon=UBERON:0002390!1.10e-17!102;UBERON:0003061!1.10e-17!102;UBERON:0002193!1.33e-14!112;UBERON:0002371!4.86e-13!80;UBERON:0001474!1.37e-11!86;UBERON:0002405!9.14e-11!115;UBERON:0004765!2.63e-09!101;UBERON:0001434!2.63e-09!101;UBERON:0002384!3.39e-07!375
}}
}}

Revision as of 14:40, 21 May 2012


Full id: C3787_CD14_Eosinophils_Neutrophils_Peripheral_aorta_Natural_CD4



Phase1 CAGE Peaks

Hg19::chr19:39900896..39900918,+p@chr19:39900896..39900918
+
Hg19::chr19:39900924..39900973,+p@chr19:39900924..39900973
+
Hg19::chr19:39901623..39901638,+p@chr19:39901623..39901638
+


Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data


No results for this coexpression

Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data


No GOStat results

Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br><br>


Cell Type
Ontology termp-valuen
leukocyte1.08e-28140
CD14-positive, CD16-negative classical monocyte3.79e-2342
nongranular leukocyte9.06e-23119
hematopoietic stem cell1.88e-22172
angioblastic mesenchymal cell1.88e-22172
classical monocyte2.24e-2245
hematopoietic lineage restricted progenitor cell1.28e-21124
hematopoietic oligopotent progenitor cell2.25e-21165
hematopoietic multipotent progenitor cell2.25e-21165
hematopoietic cell1.87e-20182
myeloid leukocyte2.34e-1876
granulocyte monocyte progenitor cell1.70e-1471
macrophage dendritic cell progenitor3.27e-1465
monopoietic cell2.79e-1363
monocyte2.79e-1363
monoblast2.79e-1363
promonocyte2.79e-1363
myeloid cell4.95e-13112
common myeloid progenitor4.95e-13112
myeloid lineage restricted progenitor cell5.33e-1370
lymphocyte2.24e-0853
common lymphoid progenitor2.24e-0853
lymphoid lineage restricted progenitor cell3.70e-0852
connective tissue cell9.94e-08365
mesenchymal cell1.38e-07358
intermediate monocyte7.53e-079
CD14-positive, CD16-positive monocyte7.53e-079
Uber Anatomy
Ontology termp-valuen
hematopoietic system1.10e-17102
blood island1.10e-17102
hemolymphoid system1.33e-14112
bone marrow4.86e-1380
bone element1.37e-1186
immune system9.14e-11115
skeletal element2.63e-09101
skeletal system2.63e-09101
connective tissue3.39e-07375


Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data


Novel motifs



JASPAR motifs

Motifs-log10(p-value)

{{{tfbs_overrepresentation_jaspar}}}



ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data


No analysis results for this cluster

Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data


This analysis result is provided for C0 - C305 clusters.